Impact News +++ Tilray- und Canopy Growth-Aktien knüpfen an Freitagsrally an - Hohes Anlegerinteresse (Finanzen.net) +++ CANOPY GROWTH Aktie +11,43%

SWEDISH ORPHAN Aktie

>SWEDISH ORPHAN Aktienkurs

29.74 EUR -1.7% (Tradegate)

Ask: 29.9 EUR / 170 Stück

Bid: 29.86 EUR / 170 Stück

Tagesumsatz: 1062 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>SWEDISH ORPHAN Performance

1 Woche: -2,4%

1 Monat: -1,2%

3 Monate: +23,2%

6 Monate: +13,1%

1 Jahr: +11,3%

laufendes Jahr: +10,4%

>SWEDISH ORPHAN Aktie

Name:

SWEDISH ORPHAN BIOVITRUM

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0000872095 / A0LA5K

Symbol/ Ticker:

B6E (Frankfurt)

Kürzel:

FRA:B6E, ETR:B6E, B6E:GR

Index:

Webseite:

https://www.sobi.com/

Profil:

Swedish Orphan Biovitrum AB is an international bi..
>Volltext..

Marktkapitalisierung:

10535.13 Mio. EUR

Unternehmenswert:

11667.88 Mio. EUR

Umsatz:

2512.33 Mio. EUR

EBITDA:

1576.21 Mio. EUR

Nettogewinn:

1.17 Mio. EUR

Gewinn je Aktie:

0.01 EUR

Schulden:

1225.77 Mio. EUR

Liquide Mittel:

93.72 Mio. EUR

Operativer Cashflow:

665.7 Mio. EUR

Bargeldquote:

0.07

Umsatzwachstum:

12.27%

Gewinnwachstum:

-99.62%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SWEDISH ORPHAN

Letzte Datenerhebung:

15.12.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 344.66 Mio. St.

Frei handelbar: 52%

Leerverk. Aktien: -

Rückkaufquote: -0.04%

Mitarbeiter: 1840

Umsatz/Mitarb.: 1.08 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 8.54%

Bewertung:

KGV: -

KGV lG: 56.39

KUV: 4

KBV: 3.21

PEG-Ratio: -

EV/EBITDA: 7.4

Rentabilität:

Bruttomarge: 41.79%

Gewinnmarge: 0.05%

Operative Marge: 25.85%

Managementeffizenz:

Gesamtkaprendite: 0.02%

Eigenkaprendite: 0.04%

>Peer Group

Es sind 149 Aktien bekannt.

>SWEDISH ORPHAN Chart & Kurs - Tradegate

>SWEDISH ORPHAN News

15.12.25 - 08:00	Sobi To Acquire Arthrosi Therapeutics (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) has entered into an acquisition agreement with Arthrosi Therapeutics, which was invested in and incubated by Viva Biotech......

15.12.25 - 07:30	Viva Biotech′s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. (PR Newswire)
	STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will......

15.12.25 - 07:09	Viva Biotech′s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. (PR Newswire)
	STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will......

23.10.25 - 16:12	Swedish Orphan Biovitrum AB reports Q3 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.10.25 - 10:48	Sobi Q3 Adj. EBITA Rises (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB reported a third quarter loss of 2.89 billion Swedish kronor compared to profit of 1.46 billion kronor, prior year. Loss per share ......

20.10.25 - 10:16	Sobi Q3 2025 report: Accelerated growth and portfolio momentum (PR Newswire)
	STOCKHOLM, Oct. 20, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025 Total revenue increased 13 per cent, 21 per cent at constant exchange rates, (CER)1, to SEK 7,776 M (6,894) Haematology revenue......

20.10.25 - 09:57	Sobi Q3 2025 report: Accelerated growth and portfolio momentum (PR Newswire)
	STOCKHOLM, Oct. 20, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025 Total revenue increased 13 per cent, 21 per cent at constant exchange rates, (CER)1, to SEK 7,776 M (6,894) Haematology revenue......

20.10.25 - 05:48	Sobi Raises FY25 Outlook (AFX)
	STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY, BIOVF, SOBI.ST) or Sobi announced that it raised its outlook for 2025. As part of this update, the company will adjust its financial repor......

19.10.25 - 22:06	Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report (PR Newswire)
	STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such......

19.10.25 - 22:03	Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report (PR Newswire)
	STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such......

30.09.25 - 08:27	New number of shares and votes in Sobi (PR Newswire)
	STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are common shares. The total number of votes is 357,412,837. The increase in the number of common shares......

30.09.25 - 08:24	New number of shares and votes in Sobi (PR Newswire)
	STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are common shares. The total number of votes is 357,412,837. The increase in the number of common shares......

29.08.25 - 08:30	New number of shares and votes in Sobi (PR Newswire)
	STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The......

29.08.25 - 08:24	New number of shares and votes in Sobi (PR Newswire)
	STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The......

21.08.25 - 13:01	Sobi has completed issues of class C shares (PR Newswire)
	STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class......

21.08.25 - 12:57	Sobi has completed issues of class C shares (PR Newswire)
	STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class......

25.07.25 - 13:54	Sobi North America Announces Approval Of Doptelet For Pediatric ITP (AFX)
	STOCKHOLM (dpa-AFX) - Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced the FDA approved Doptelet or avatrombopag for the treatment of thrombocytopenia in ......

16.07.25 - 12:12	Swedish Drugmaker Sobi Doesn′t See Pharma Tariffs as ′Imminent′ (Bloomberg)
	Drugmaker Swedish Orphan Biovitrum AB's Chief Executive Officer Guido Oelkers said he doesn't think tariff threats on the pharmaceutical industry are likely to materialize imminently....

16.07.25 - 08:48	Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.07.25 - 08:30	Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum (PR Newswire)
	STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER)1, to SEK 6,175 M (5,442) Haematology revenue......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Gott lebt in der Musik. - Sprichwort Indien

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram